Drug Approval | April 09, 2025
Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
The introduction of Coveris’ sleeve-to-sleeve PCR model complements sectors such as bottling where an established recycling infrastructure exists
GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Subscribe To Our Newsletter & Stay Updated
